Authors: Kamphuis AEM, Salvadori N, Mujuru HA, Bwakura-Dangarembizi M, Kisitu GP, Matovu F, Kaudha E, Mulindwa A, Jacobs TG, Than-in-at K, Cressey TR, Nardone A, Lallemant M, Colbers A, Burger DM Published in: The Lancet [button...
Musakanya Chingandu
Simulation-Based Predictions to Support the Development of a Pediatric Fixed-Dose Combination of Dolutegravir/Emtricitabine/Tenofovir Alafenamide Fumarate
Authors: Waalewijn H, Bevers LAH, Lewis LL, Louey MD, Kawakatsu S, Zheng Y, Giaquinto C, Nardone A, Burger DM, ter Heine R, Colbers A, Svensson EM. Published in: Clinical Pharmacokinetics [button link="https://link.springer.com/article/10.1007/s40262-026-01671-z"...
Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy Volunteers
Authors: Kamphuis A.E.M., Burger D, Bevers L.A.H. Published in: Radobud Univeristy
Closing the paediatric HIV treatment gap
This article was written by Anne Kamphuis and Prof David Burger, Radboud University Medical Centre. It is taken from the Penta 2025 Annual Report. Despite significant advances in HIV treatment in recent years, these have mainly benefited adults. Children have...
Efficacy of second-line dolutegravir- versus boosted protease inhibitor-based ART in children and adolescents living with HIV at 96 and 144 weeks: pooled analysis of the ODYSSEY and CHAPAS-4 trials
Authors: Amuge P, Jackson C, Bwakura-Dangarembizi M, Kityo C, Lugemwa A, Chabala C, Nyathi M, Nduna B, Musoke P, Yawe I, Kaudha E, Musoro G, Ankunda R, Bbuye D, Violar A, Variava E, Archary M, Cotton M, Cressey RT, Ndebele W, Mulenga V, Mwamabazi M, Szubert A, White...
UNIVERSAL 1 trial enrols first patients
A significant milestone has been reached in the fight against paediatric HIV with the enrolment of the first participants in the UNIVERSAL 1 trial. This achievement is a testament to the tremendous effort and dedication of the site staff in Uganda and Zimbabwe. ...
Optimising Paediatric HIV Treatment: Recent Developments and Future Directions
Authors: Kamphuis A.E.M., Bamford A., Tagarro A., Cressey AT, Bekker A, Amuge P, Mujuru HA, Ndongo AF, Diack A, Compagnucci A, Lallemant M, Colbers A, Turkova A. Published in: Pediatric Drugs [button link="https://link.springer.com/article/10.1007/s40272-024-00656-4"...
UNIVERSAL data supports Laurus Labs US FDA submission for approval of novel protease inhibitor
Laurus Labs has submitted an application to the US Food and Drug Administration (FDA) for the tentative approval of paediatric Darunavir/ritonavir (pDRV/r (120/20 mg)). UNIVERSAL is the first product development project from the World Health Organisation's (WHO) GAP-F...
UNIVERSAL submits data to the FDA to support the dosing of a new drug combination to treat HIV in children
The UNIVERSAL project is proud to announce the submission of a pharmacokinetic modelling and simulation analysis to the US Food and Drug Administration (FDA). This submission aims to support the new dosing of Darunavir/Ritonavir (DRV/r) 120/20mg, combined in one...
UNIVERSAL’s potential impact on the health of children living with HIV, told by Dr Vivian Mumbiro
In recent years, advancements in medical research have paved the way for an array of treatment options for children living with HIV. The efforts of scientists and researchers globally, have led to continuous refinement and improvement of existing regimens. Dr. Vivian...


